{"id":71225,"date":"2026-03-09T21:02:47","date_gmt":"2026-03-09T20:02:47","guid":{"rendered":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/"},"modified":"2026-03-09T21:02:47","modified_gmt":"2026-03-09T20:02:47","slug":"tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva","status":"publish","type":"post","link":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/","title":{"rendered":"<div>Tumore seno, Coco &#8220;La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva&#8221;<\/div>"},"content":{"rendered":"<p>    <video-js id=\"videojs69eb779c61bf5\" class=\"vjs-big-play-centered\" controls preload=\"auto\" playsinline data-setup='{\"fluid\": true}'>\r\n        <source src=\"https:\/\/video.italpress.com\/play\/mp4\/video\/O0EE\" type=\"video\/mp4\" \/>\r\n    <\/video-js>\r\n           <br \/>\n<\/p>\n<div> MILANO (ITALPRESS) &#8211; Novartis ha annunciato l&#8217;approvazione da parte dell&#8217;Agenzia Italiana del Farmaco (Aifa) della rimborsabilit\u00e0 per ribociclib in associazione alla terapia endocrina (ET) con inibitori dell&#8217;aromatasi, per il trattamento adiuvante dei pazienti con tumore al seno in fase iniziale, positivo per i recettori ormonali e negativo per il recettore 2 del fattore di crescita epidermico umano (HR+\/HER2-), ad alto rischio di recidiva, che include tutti i pazienti con malattia linfonodale positiva indipendentemente dalle altre caratteristiche cliniche. &#8220;Per noi, oggi, \u00e8 motivo di grande orgoglio poter annunciare l&#8217;approvazione del nostro inibitore delle cicline che rappresenta un&#8217;importante novit\u00e0 nell&#8217;ambito del carcinoma mammario in fase localizzata&#8221;, sottolinea Paola Coco, Chief Scientific Officer and Medical Affairs Head di Novartis. &#8220;La novit\u00e0 terapeutica permette alle pazienti di ridurre in maniera significativa &#8211; del 28% &#8211; il rischio di recidiva che sappiamo, purtroppo, colpire una donna su cinque dopo che il tumore \u00e8 stato rimosso in maniera chirurgica. Quindi, consideriamo che pi\u00f9 di una donna su quattro riesce a non recidivare grazie a questa opzione terapeutica&#8221;.<\/p>\n<p>xm4\/fsc\/mca1<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MILANO (ITALPRESS) &#8211; Novartis ha annunciato l&#8217;approvazione da parte dell&#8217;Agenzia Italiana del Farmaco (Aifa) della rimborsabilit\u00e0 per ribociclib in associazione alla terapia endocrina (ET) con inibitori dell&#8217;aromatasi, per il trattamento adiuvante dei pazienti con tumore al seno in fase iniziale, positivo per i recettori ormonali e negativo per il recettore 2 del fattore di crescita [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":71226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"video","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[1171],"tags":[],"class_list":["post-71225","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-video","post_format-post-format-video"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tumore seno, Coco &quot;La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva&quot; - Live Magazine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tumore seno, Coco &quot;La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva&quot; - Live Magazine\" \/>\n<meta property=\"og:description\" content=\"MILANO (ITALPRESS) &#8211; Novartis ha annunciato l&#8217;approvazione da parte dell&#8217;Agenzia Italiana del Farmaco (Aifa) della rimborsabilit\u00e0 per ribociclib in associazione alla terapia endocrina (ET) con inibitori dell&#8217;aromatasi, per il trattamento adiuvante dei pazienti con tumore al seno in fase iniziale, positivo per i recettori ormonali e negativo per il recettore 2 del fattore di crescita [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/\" \/>\n<meta property=\"og:site_name\" content=\"Live Magazine\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LiveMag\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T20:02:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.livemag.it\/wp-content\/uploads\/2024\/02\/ograph.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"italpress\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@LiveNotizie\" \/>\n<meta name=\"twitter:site\" content=\"@LiveNotizie\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"italpress\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/\"},\"author\":{\"name\":\"italpress\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#\\\/schema\\\/person\\\/b62c5f44451fdcdaeb0afe6c2424e73c\"},\"headline\":\"Tumore seno, Coco &#8220;La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva&#8221;\",\"datePublished\":\"2026-03-09T20:02:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/\"},\"wordCount\":202,\"publisher\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.livemag.it\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/O0EE.jpg\",\"articleSection\":[\"Video\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/\",\"url\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/\",\"name\":\"Tumore seno, Coco \\\"La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva\\\" - Live Magazine\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.livemag.it\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/O0EE.jpg\",\"datePublished\":\"2026-03-09T20:02:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.livemag.it\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/O0EE.jpg\",\"contentUrl\":\"https:\\\/\\\/www.livemag.it\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/O0EE.jpg\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/2026\\\/03\\\/09\\\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.livemag.it\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tumore seno, Coco &#8220;La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva&#8221;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#website\",\"url\":\"https:\\\/\\\/www.livemag.it\\\/\",\"name\":\"Live Magazine\",\"description\":\"Varie ed eventi\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.livemag.it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#organization\",\"name\":\"LiveMag\",\"alternateName\":\"LiveMag News ed eventi\",\"url\":\"https:\\\/\\\/www.livemag.it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.livemag.it\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/immagine-sito.jpg\",\"contentUrl\":\"https:\\\/\\\/www.livemag.it\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/immagine-sito.jpg\",\"width\":696,\"height\":696,\"caption\":\"LiveMag\"},\"image\":{\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/LiveMag\\\/\",\"https:\\\/\\\/x.com\\\/LiveNotizie\",\"https:\\\/\\\/www.instagram.com\\\/livemag\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.livemag.it\\\/#\\\/schema\\\/person\\\/b62c5f44451fdcdaeb0afe6c2424e73c\",\"name\":\"italpress\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b6a21695fc713ce7ee312cf57c97e2e641feb365be72d8745574d3c3e2b59066?s=96&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b6a21695fc713ce7ee312cf57c97e2e641feb365be72d8745574d3c3e2b59066?s=96&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b6a21695fc713ce7ee312cf57c97e2e641feb365be72d8745574d3c3e2b59066?s=96&r=g\",\"caption\":\"italpress\"},\"description\":\"Italpress \u00e8 un'agenzia di stampa italiana a carattere nazionale.\",\"url\":\"https:\\\/\\\/www.livemag.it\\\/index.php\\\/author\\\/italpress\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tumore seno, Coco \"La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva\" - Live Magazine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/","og_locale":"it_IT","og_type":"article","og_title":"Tumore seno, Coco \"La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva\" - Live Magazine","og_description":"MILANO (ITALPRESS) &#8211; Novartis ha annunciato l&#8217;approvazione da parte dell&#8217;Agenzia Italiana del Farmaco (Aifa) della rimborsabilit\u00e0 per ribociclib in associazione alla terapia endocrina (ET) con inibitori dell&#8217;aromatasi, per il trattamento adiuvante dei pazienti con tumore al seno in fase iniziale, positivo per i recettori ormonali e negativo per il recettore 2 del fattore di crescita [&hellip;]","og_url":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/","og_site_name":"Live Magazine","article_publisher":"https:\/\/www.facebook.com\/LiveMag\/","article_published_time":"2026-03-09T20:02:47+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.livemag.it\/wp-content\/uploads\/2024\/02\/ograph.jpg","type":"image\/jpeg"}],"author":"italpress","twitter_card":"summary_large_image","twitter_creator":"@LiveNotizie","twitter_site":"@LiveNotizie","twitter_misc":{"Scritto da":"italpress","Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/#article","isPartOf":{"@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/"},"author":{"name":"italpress","@id":"https:\/\/www.livemag.it\/#\/schema\/person\/b62c5f44451fdcdaeb0afe6c2424e73c"},"headline":"Tumore seno, Coco &#8220;La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva&#8221;","datePublished":"2026-03-09T20:02:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/"},"wordCount":202,"publisher":{"@id":"https:\/\/www.livemag.it\/#organization"},"image":{"@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/#primaryimage"},"thumbnailUrl":"https:\/\/www.livemag.it\/wp-content\/uploads\/2026\/03\/O0EE.jpg","articleSection":["Video"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/","url":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/","name":"Tumore seno, Coco \"La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva\" - Live Magazine","isPartOf":{"@id":"https:\/\/www.livemag.it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/#primaryimage"},"image":{"@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/#primaryimage"},"thumbnailUrl":"https:\/\/www.livemag.it\/wp-content\/uploads\/2026\/03\/O0EE.jpg","datePublished":"2026-03-09T20:02:47+00:00","breadcrumb":{"@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/#primaryimage","url":"https:\/\/www.livemag.it\/wp-content\/uploads\/2026\/03\/O0EE.jpg","contentUrl":"https:\/\/www.livemag.it\/wp-content\/uploads\/2026\/03\/O0EE.jpg","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.livemag.it\/index.php\/2026\/03\/09\/tumore-seno-coco-la-novita-terapeutica-di-novartis-riduce-il-rischio-recidiva\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.livemag.it\/"},{"@type":"ListItem","position":2,"name":"Tumore seno, Coco &#8220;La novit\u00e0 terapeutica di Novartis riduce il rischio recidiva&#8221;"}]},{"@type":"WebSite","@id":"https:\/\/www.livemag.it\/#website","url":"https:\/\/www.livemag.it\/","name":"Live Magazine","description":"Varie ed eventi","publisher":{"@id":"https:\/\/www.livemag.it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.livemag.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.livemag.it\/#organization","name":"LiveMag","alternateName":"LiveMag News ed eventi","url":"https:\/\/www.livemag.it\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.livemag.it\/#\/schema\/logo\/image\/","url":"https:\/\/www.livemag.it\/wp-content\/uploads\/2024\/02\/immagine-sito.jpg","contentUrl":"https:\/\/www.livemag.it\/wp-content\/uploads\/2024\/02\/immagine-sito.jpg","width":696,"height":696,"caption":"LiveMag"},"image":{"@id":"https:\/\/www.livemag.it\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LiveMag\/","https:\/\/x.com\/LiveNotizie","https:\/\/www.instagram.com\/livemag\/"]},{"@type":"Person","@id":"https:\/\/www.livemag.it\/#\/schema\/person\/b62c5f44451fdcdaeb0afe6c2424e73c","name":"italpress","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/b6a21695fc713ce7ee312cf57c97e2e641feb365be72d8745574d3c3e2b59066?s=96&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b6a21695fc713ce7ee312cf57c97e2e641feb365be72d8745574d3c3e2b59066?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b6a21695fc713ce7ee312cf57c97e2e641feb365be72d8745574d3c3e2b59066?s=96&r=g","caption":"italpress"},"description":"Italpress \u00e8 un'agenzia di stampa italiana a carattere nazionale.","url":"https:\/\/www.livemag.it\/index.php\/author\/italpress\/"}]}},"jetpack_featured_media_url":"https:\/\/www.livemag.it\/wp-content\/uploads\/2026\/03\/O0EE.jpg","_links":{"self":[{"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/posts\/71225","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/comments?post=71225"}],"version-history":[{"count":0,"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/posts\/71225\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/media\/71226"}],"wp:attachment":[{"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/media?parent=71225"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/categories?post=71225"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.livemag.it\/index.php\/wp-json\/wp\/v2\/tags?post=71225"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}